By Karen Roman ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from April 24-28, 2025. The findings confirm elevated inflammatory...

Tech Edge hosted a fireside chat on April 22 at Nasdaq MarketSite with Jason Matuszewski, Chief Executive Officer of BioStem Technologies, Inc. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed why the company’s 2024 revenue surged 18x,...

By Karen Roman March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma. The test will take place at leading cancer centers across the country, with the first...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. The added drugs are lisaftoclax and olverembatinib; the former used to diagnose...

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its multi-source digital imaging system, Nanox.ARC X, received FDA 510(k) clearance for general use. The Nanox.ARC X has a simplified “plug and play” one-day installation feature and allows remote software upgrades,...

Tech Edge will be attending the RSA Conference 2025 at the Moscone Center in San Francisco on April 28 – May 1, 2025, for onsite interviews in a multi-camera 4K television studio. This event is the country’s leading cybersecurity conference...

By Exec Edge Editorial Staff Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focused on US and...

Visit Exec Edge Research for Full Report By Rayk Riechmann How about steak and a show for dinner and best-in-class growth for dessert? Investors can enjoy just that with The ONE Group Hospitality, Inc. (Nasdaq: STKS), operator of 167 full-service,...

By Karen Roman Biopharmaceutical company ReAlta Life Sciences said it designated immunologist Laurie Glimcher, M.D., to its Board of Directors. Dr. Glimcher is renowned for her 35 years of work in cancer research, and she is the Richard and Susan...

Contact: Executives-Edge.com Editor@executives-edge.com